Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

NCT04216355 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

MDS-EB

Interventions

DRUG: Azacitidine
DRUG: CAG Protocol

Sponsor

Fujian Medical University